There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agile Therapeutics (AGRX – Research Report) and SELLAS Life Sciences Group (SLS – Research Report) with bullish sentiments.
Agile Therapeutics (AGRX)
William Blair analyst Tim Lugo maintained a Buy rating on Agile Therapeutics on June 1. The company’s shares closed last Wednesday at $1.26, close to its 52-week low of $1.07.
According to TipRanks.com, Lugo is a 5-star analyst with an average return of 16.5% and a 48.5% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Collegium Pharmaceutical, and Adamas Pharmaceuticals.
Agile Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $6.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.